Evidence map›Paper›PMID 26093865›Full record

Observational studyAmerican heart journal2015

Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.

Robin Mathews, Tracy Y Wang, Emily Honeycutt, Timothy D Henry, Marjorie Zettler, Michael Chang, Gregg C Fonarow, Eric D Peterson, TRANSLATE-ACS Study Investigators

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in American heart journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Medication Discontinuation in the IMPROVE-IT Trial.Circulation. Cardiovascular quality and outcomes · 2019
    Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Population-Level Gaps in Coronary Artery Disease Care: A Focused Review.Methodist DeBakey cardiovascular journal · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Robin MathewsDuke Clinical Research Institute, Durham, NC. Electronic address: robin.mathews@duke.edu.
Tracy Y WangDuke Clinical Research Institute, Durham, NC.
Emily HoneycuttDuke Clinical Research Institute, Durham, NC.
Timothy D HenryMinneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN.
Marjorie ZettlerLilly, USA, LLC, Indianapolis, IN.
Michael ChangMercy Heart Vascular Institute, Sacramento, CA.
Gregg C FonarowAhmanson-UCLA Cardiomyopathy Center, University of California at Los Angeles, Los Angeles, CA.
Eric D PetersonDuke Clinical Research Institute, Durham, NC.
TRANSLATE-ACS Study Investigators
Clinical Research Institute · USAbbott Northwestern Hospital · USDurham University · GBEli Lilly (United States) · USMercy General Hospital · USUniversity of California, Los Angeles · US

Funding

Inter-disciplinary Program for Training and Mentoring in CER Methods and PracticeKM1CA156687 · NCI · DUKE UNIVERSITY · PI ABERNETHY, AMY P., DELONG, ELIZABETH R. · 2010 to 2010
$2.4M
NCI NIH HHS KM1 CA156687NCI NIH HHS KM1CA156687
6 · The paper itself

Abstract

backgroundPersistent use of secondary prevention therapies after acute myocardial infarction (MI) is critical to optimizing long-term outcomes.

methodsMedication persistence was assessed among 7,955 MI patients in 216 hospitals participating in the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome study from 2010 to 2012. Persistence was defined as continuation of aspirin, adenosine diphosphate receptor inhibitors, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins from discharge to 6 months post-MI. Multivariable logistic regression modeling was used to determine factors associated with nonpersistence, defined as <80% persistence with all medication classes.

resultsOverall, 31% of MI patients stopped taking a least 1 medication by 6 months. The most common reasons cited for medications discontinuation were side effects and physician instruction (57%), whereas financial concerns were cited in 8% overall. After multivariable modeling, black race (odds ratio 1.36, 95% CI 1.15-1.62), older age (odds ratio 1.07, 95% CI 1.02-1.12), atrial fibrillation (odds ratio 1.67, 95% CI 1.33-2.09), dialysis (odds ratio 1.79, 95% CI 1.15-2.78), and depression (odds ratio 1.22, 95% CI 1.02-1.45) were associated with lower likelihood of persistence. Private insurance (odds ratio 0.85, 95% 0.76-0.95), prescription cost assistance (odds ratio 0.63, 95% CI 0.54-0.75), and outpatient follow-up arranged before discharge (odds ratio 0.89, 95% CI 0.80-0.99) were associated with higher persistence.

conclusionsNearly one-third of MI patients are no longer persistent with their prescribed medications by 6 months. Patients at high risk for nonpersistence may be identified by clinical and sociodemographic features. These observations underscore key opportunities to optimize longitudinal use of secondary prevention therapies.

Indexed as

Drug MonitoringSecondary PreventionAdrenergic beta-AntagonistsAgedAge FactorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAspirinBlack or African AmericanDepressionFemaleHispanic or LatinoHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLogistic ModelsLongitudinal StudiesAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAspirinHydroxymethylglutaryl-CoA Reductase InhibitorsPlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists

Identifiers

PMID26093865
PMCPMC4808054
OpenAlexW2077338998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.